Home
overview

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new  FDA  draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.


Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.

At this years conference there will once again be an array of networking opportunities:

  • Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
  • More than 4 hours of networking during the conference days
  • Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year


Key reasons to attend:

  • See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
  • Explore the therapeutic potential of  adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis 
  • Listen to how the latest platform trial case studies – such as that of  the EPAD project and the MS Society  initiative, are impacting pharmaceutical development
  • Delve into the long-standing discussion of  Bayesian vs. frequentist designs
  • Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward
     

Who should attend:

  • Biostatisticians
  • Clinical project managers
  • Clinical research advisors
  • Clinical Trials Directors
  • Clinical scientists
  • Statisticians
  • Quantitative scientists

     

Almac Clinical Technologies LLC; Amgen; AstraZeneca; BeiGene; Berry Consultants, LLP; Boehringer-Ingelheim; Chiesi Farmaceutici; DEBIOPHARM INTERNATIONAL SA; Dr. Willmar Schwabe GmbH & Co. KG; Eli Lilly International Corporation; European Medicines Agency (EMA); Ferring Pharmaceuticals A/S; Fraunhofer Institute for Algorithms and Scientific Computing; GCE Solutions; Glenmark Pharmaceuticals; GSK; Highbury Regulatory Science; Janssen; Lundbeck Pharma; Medtronic; Menarini Ricerche SpA; Merck & Company; Mevia; MHRA; MRC Biostatistics Unit; National Institute of Allergy and Infectious Diseases ; Orion Corporation Orion Pharma; Oslo University Hospital; Roche Products Ltd; Sanofi Aventis; SDS; TFS Trial Form Support; TFS, S.L. (CIF: B-60569175); Transgene SA; UCB Pharma Limited; University Of Bath; University of Reading; Lancaster University

Conference programme

8:30 Registration & Coffee

8:50 Chairman's Opening Remarks

Alex Sverdlov

Alex Sverdlov, Director, Statistical Scientist, Novartis

9:00 Statistical and design considerations in personalised medicine

Sandeep Menon

Sandeep Menon, Vice President, Pfizer Inc
View Bio

  • Identifying genetic, genomic and clinical characteristics to predict patient susceptibility
  • Biomarkers and the challenges in their use for diagnostics
  • Selecting appropriate designs to determine biomarker performance, reliability and regulatory acceptance
  • Case studies for biomarker driven trials
  • 9:40 Adaptive designs in multiple sclerosis clinical trials

    Emma  Gray

    Emma Gray, MS Society - Head of Clinical Trials, MS National Centre (MSNC)
    View Bio

  • Initiative to establish platform trial
  • The practicalities of setting up platform trials
  • Methodological challenges in MS trial design
  • Ethical and patient perspective on adaptive designs

     

  • 10:20 Morning Coffee

    10:50 Adaptive signature designs for cancer vaccines

    Andrea Callegaro

    Andrea Callegaro, Senior Manager, Biostatistician, GSK Vaccines
    View Bio

  • Mage-A3: a double-blind, randomised, placebo-controlled, phase 3 trial
  • The practical and operational considerations of immunotherapeutic adaptive designs
  • Futility for subgroup analyses in adaptive signature design
  • The future of adaptive designs for cancer vaccines
  • 11:30 The European Prevention of Alzheimer’s Disease platform trial

    Philip  Hougaard

    Philip Hougaard, Vice President, Biometrics, H. Lundbeck A/S
    View Bio

  • EPAD is a public-private partnership running two connected trials:
  • A longitudinal cohort study identifying subjects with biomarker evidence of early Alzheimer’s
  • An adaptive platform trial for Proof-of-concept testing of new preventive treatments, recruiting from the first trial
  • Advantages and disadvantages of testing drugs in this setup compared to classical one-drug trials
  • 12:10 Networking Lunch

    13:10 An industry outlook on adaptive designs in clinical trials

    Christine Fletcher

    Christine Fletcher, Executive Director Biostatistics, Amgen
    View Bio

  • Innovations of adaptive designs in clinical trials
  • How has the use of adaptive designs in clinical trials developed?
  • Views on the draft FDA guidance on adaptive designs
  • Heads of Medicines Agencies: Clinical Trials Facilitation Group practical implications
  • 13:50 The evolution of adaptiveness

    Solange Corriol-Rohou

    Solange Corriol-Rohou, Senior Director Regulatory Affairs and Policy, EU, AstraZeneca
    View Bio

  • Recent updates in European guidance
  • The MAPPs engagement process
  • Critical questions to be asked
  • Adaptive approaches to bringing drugs to the market
  • 14:30 Afternoon Tea

    15:00 A regulatory perspective of adaptive design trials

    Beatrice Panico

    Beatrice Panico , Medical Assessor , Medicines and Healthcare Products Regulatory Agency
    View Bio

  • Initial Clinical Trial Authorisation (CTA): points to consider
  • Regulatory points to consider for submissions with substantial amendments
  • Safety considerations
  • 15:40 Using Estimand Framework in Adaptive Designs: The implication of ICH E9 R(1)

    Macaulay Okwuokenye

    Macaulay Okwuokenye, Syros Pharmaceuticals, Principal Biostatistician, Syros Pharmaceuticals

  • ICH E9(R1) and adaptive clinical trials
  • Using estimand framework in adaptive clinical trials
  • Design challenges that ICH E9(R1) might bring to adaptive designs
  • Impact of ICH E9(R1) on the analysis of adaptive clinical trials
  • 16:20 Chairman’s Closing Remarks and Close of Day One

    Alex Sverdlov

    Alex Sverdlov, Director, Statistical Scientist, Novartis

    8:30 Registration & Coffee

    8:50 Chairman's Opening Remarks

    Tom Parke

    Tom Parke, Director of Software Solutions, Berry Consultants, LLP
    View Bio

    9:00 Digital therapeutics: an integral component of digital innovation in drug development

    Alex Sverdlov

    Alex Sverdlov, Director, Statistical Scientist, Novartis

  • The potential for reducing current costs of medical care
  • The unmet medical needs addressed by digital therapeutics
  • Emerging pathways to regulatory approval
  • How innovative business models are enabling further growth in digital therapeutics
  • 9:40 Applying adaptive designs in industry

    Frank Fleischer

    Frank Fleischer, Team Leader Clinical Biostatistics, Boehringer-Ingelheim
    View Bio

  • Overview of adaptive designs at BI
  • Joint escalation models in oncology dose finding
  • Early phase basket designs and GoNoGo decision making
  • Blinded sample size reassessment – is there a future?
  • 10:20 Morning Coffee

    10:50 Extrapolation in clinical trials and beyond

    Simon Wandel

    Simon Wandel, Associate Director Statistical Methodologist, Novartis Pharmaceuticals
    View Bio

  • Basics of extrapolation: when is it applicable - and when not
  • Extrapolation from adults to children: “adaptive” borrowing
  • Bridging studies
  • Beyond individual studies: extrapolation via mixture models for meta-analysis
  • 11:30 Continuous decision making within a clinical trial

    Paul Frewer

    Paul Frewer, Early Clinical Development, AstraZeneca
    View Bio

  • Overview of Decision Making in Early clinical development at AstraZeneca
  • Incorporating continuous decision making into the framework
  • Standardizing tools/ figures to convey the information
  • Statistical risks and considerations in adopting this approach
  • 12:10 Networking Lunch

    13:10 Response-adaptive designs

    Sofia Villar

    Sofia Villar, postdoctoral research associate , MRC Centre

  • The benefits of forward looking response-adaptive randomisation in adaptive designs
  • Trials for rare diseases & finding treatments that work subgroups
  • Type 1 error inflation due to an unknown time trend over the course of the trial
  • 13:50 Panel Discussion: Bayesian vs. frequentist designs incorporating multiple treatment arms

  • Response-adaptive randomisation
  • Triangular tests
  • Dropping poorly-performing arms in multi-arm multi-stage designs
  • Flexibility in Bayesian vs. frequentist designs
  • Michael Proschan

    Michael Proschan, Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
    View Bio

    Kaspar Rufibach

    Kaspar Rufibach, Principal Statistical Scientist, F. Hoffman-La Roche AG
    View Bio

    Alex Sverdlov

    Alex Sverdlov, Director, Statistical Scientist, Novartis

    Sofia Villar

    Sofia Villar, postdoctoral research associate , MRC Centre

    14:30 Planning a phase 3 trial with time-to-event endpoint

    Kaspar Rufibach

    Kaspar Rufibach, Principal Statistical Scientist, F. Hoffman-La Roche AG
    View Bio

  • The MIRROS phase 3 trial
  • Futility interim analysis using a mechanistic simulation model
  • Sample size planning
  • Exploration of operating characteristics of the futility interim analysis
  • 15:10 Afternoon Tea

    15:40 Defining decision rules based on simulated development programs

    Heiko Goette

    Heiko Goette, Merck, Merck & Company
    View Bio

  • Go/no go decision after phase 2 and futility analysis in phase 3 trials based on estimated probability of success
  • Probability of success is estimated using simulations taking into account observed association between short-term and long-term endpoint from phase 2
  • Simulation of complete phase 2 and 3 development program allows to define appropriate decision boundaries
  • 16:20 Chairman’s Closing Remarks and Close of Day Two

    Tom Parke

    Tom Parke, Director of Software Solutions, Berry Consultants, LLP
    View Bio

    +

    FEATURED SPEAKERS

    Andrea Callegaro

    Andrea Callegaro

    Senior Manager, Biostatistician, GSK Vaccines
    Beatrice Panico

    Beatrice Panico

    Medical Assessor , Medicines and Healthcare Products Regulatory Agency
    Christine Fletcher

    Christine Fletcher

    Executive Director Biostatistics, Amgen
    Emma  Gray

    Emma Gray

    MS Society - Head of Clinical Trials, MS National Centre (MSNC)
    Frank Fleischer

    Frank Fleischer

    Team Leader Clinical Biostatistics, Boehringer-Ingelheim
    Heiko Goette

    Heiko Goette

    Merck, Merck & Company
    Kaspar Rufibach

    Kaspar Rufibach

    Principal Statistical Scientist, F. Hoffman-La Roche AG
    Macaulay Okwuokenye

    Macaulay Okwuokenye

    Syros Pharmaceuticals, Principal Biostatistician, Syros Pharmaceuticals
    Michael Proschan

    Michael Proschan

    Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
    Paul Frewer

    Paul Frewer

    Early Clinical Development, AstraZeneca
    Philip  Hougaard

    Philip Hougaard

    Vice President, Biometrics, H. Lundbeck A/S
    Sandeep Menon

    Sandeep Menon

    Vice President, Pfizer Inc
    Simon Wandel

    Simon Wandel

    Associate Director Statistical Methodologist, Novartis Pharmaceuticals
    Sofia Villar

    Sofia Villar

    postdoctoral research associate , MRC Centre
    Solange Corriol-Rohou

    Solange Corriol-Rohou

    Senior Director Regulatory Affairs and Policy, EU, AstraZeneca
    Tom Parke

    Tom Parke

    Director of Software Solutions, Berry Consultants, LLP

    Andrea Callegaro

    Senior Manager, Biostatistician, GSK Vaccines
    Andrea Callegaro

    Andrea Callegaro is a statistician working at GSK Vaccines (Belgium) on statistical innovation (trial designs, surrogate endpoints, high-dimensional data, exploratory analysis…).
    Before joining GSK, he worked on the analysis of micro-arrays data (Bioinformatics – Padova University), on survival data analysis (San Gerardo Hospital, Milan) and he developed survival models with skew-normal frailties (post doc with Prof. A. Azzalini, Padova University).
    For his PhD thesis, he worked on frailty models for gene-mapping (Prof. HC van Houwelingen, Leiden University)
     

    Beatrice Panico

    Medical Assessor , Medicines and Healthcare Products Regulatory Agency
    Beatrice Panico

    Maria Beatrice Panico is currently a Medical Assessor in the Clinical Trials Unit at the Medicines and Healthcare products Regulatory Agency (MHRA).
    She is a medical doctor, fully qualified in Neurology with a PhD in Neuroscience. She has extensive experience in pharmacovigilance in the pharmaceutical industry.
     

    Christine Fletcher

    Executive Director Biostatistics, Amgen
    Christine Fletcher

    Chrissie is a Regional Head in Global Biostatistical Science at Amgen and she leads a Health Technology Assessment (HTA) Biostatistics group. Chrissie has worked in the Pharmaceutical Industry for over 25 years and has experience of developing and commercialising new medicines from a variety of therapeutic areas across all phases of clinical development.

    Chrissie is currently the Vice-President of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI), and co-chair of the Clinical Development Expert Group for the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Chrissie is a Chartered Statistician and Chartered Scientist of the Royal Statistical Society (RSS). Chrissie has an MSc in Applied Statistics and a BSc (Hons) in Statistics with Management Science Techniques.
     

    Emma Gray

    MS Society - Head of Clinical Trials, MS National Centre (MSNC)
    Emma  Gray

    Emma is Head of Clinical Trials at the MS Society. She is responsible for developing and supporting the MS Society’s growing portfolio of clinical trials; collaborating with national and international funders (charity, government, other) to secure funding for MS clinical trials, the UK MS Clinical Trials Network; and more recently the Expert Consortium on Progression in MS Clinical Trials. Before joining the MS Society, she gained a PhD in molecular neuroscience and worked as a post-doctoral researcher at the MRC Centre for Neurodegeneration Research (Institute of Psychiatry, King’s College London) focusing on molecular and cellular processes associated with neurodegeneration in Alzheimer’s disease.

    Frank Fleischer

    Team Leader Clinical Biostatistics, Boehringer-Ingelheim
    Frank Fleischer

    Being a trained mathematician and statistician Frank has worked for more than 10 years in the pharmaceutical industry. He is heading a global team of statisticians at Boehringer Ingelheim focusing on statistical methodology and the implementation of innovative statistical designs into practice. In that role Frank and his team are considered with methodological questions regarding adaptive designs, statistical decision making, dose finding and Bayesian borrowing designs as well as with piloting these methods in clinical trials. Through this function several projects across different therapeutic areas and phases are supported. Formerly he has been a lead project statistician for different projects in oncology, immunology and the biosimilars.

    Heiko Goette

    Merck, Merck & Company
    Heiko Goette

    Heiko has been a Biostatistician at Merck KGaA in Germany since 2009. Before this he spent 5 years working as a research assistant at the Institute of Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University Mainz, Germany. He graduated with a Statistics major, University of Dortmund, Germany in 2004 and received his doctorate in 2008 from Johannes Gutenberg-University Mainz, Germany.

    Kaspar Rufibach

    Principal Statistical Scientist, F. Hoffman-La Roche AG
    Kaspar Rufibach

    Kaspar Rufibach does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and externally, mentors students, and interacts with external partners in industry and the academic community in various working groups. Research interests are methods to optimize study designs, advanced survival analysis, probability of success, estimands, estimation of treatment effects in subgroups, and general nonparametric statistics. Before joining Roche, Kaspar received training and worked as a statistician at the Universities of Bern, Stanford, and Zurich.

    Macaulay Okwuokenye

    Syros Pharmaceuticals, Principal Biostatistician, Syros Pharmaceuticals
    Macaulay Okwuokenye

    Michael Proschan

    Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
    Michael Proschan

    Michael Proschan has been a Mathematical Statistician in the Biostatistics Research Branch at the National Institute of Allergy and Infectious Diseases since January of 2006. Prior to coming to NIAID, he spent about 16 years at the National Heart, Lung, and Blood Institute. He co-authored the books: Statistical Monitoring of Clinical Trials: A Unified Approach, with Gordon Lan and Janet Wittes (Springer, 2006) and Essentials of Probability Theory for Statisticians, (CRC Press, 2016) with Pamela Shaw.

    Dr. Proschan received his Ph.D. in Statistics from Florida State University in 1989, M.S. in Statistics from Stanford University in 1982, and B.S. in Statistics and Mathematics (double major) from Florida State University in 1980. He became a Fellow of the American Statistical Association in 2005.
     

    Paul Frewer

    Early Clinical Development, AstraZeneca
    Paul Frewer

    Paul has been a statistician in the industry for over 20 years, working for Eli Lilly, GSK, Ipsen and AstraZeneca. He started working in post-marketing studies and slowly moved back through the phases to his current role in early clinical development. He joined AstraZeneca in 2012, and is a Associate Director, Statistics in the Early Clinical Biometrics team, supporting a number of different compounds in the oncology therapeutic area and has presented and published on the AZ decision making framework over the last few years.

    Philip Hougaard

    Vice President, Biometrics, H. Lundbeck A/S
    Philip  Hougaard

    Philip Hougaard is a biostatistician with a position as Vice President of Biometrics at Lundbeck in Denmark. He has a PhD based on a thesis on nonlinear regression and a degree as Doctor of Science based on a thesis on frailty models. He has worked in the pharmaceutical industry for 34 years, the last 16 years with Lundbeck. He is author of the book “Analysis of multivariate survival data” and more than 100 scientific papers. He is associate editor of Biostatistics and Lifetime Data Analysis. He has an honorary position as external professor at the University of Southern Denmark.

    Sandeep Menon

    Vice President, Pfizer Inc
    Sandeep Menon

    Dr. Sandeep Menon is currently the Vice President and the Head of Early Clinical Development at Pfizer Inc. and also holds Adjunct faculty positions at Boston University, Tufts University School of Medicine and Indian Institute of Management (IIM). He is the elected fellow of American Statistical Association. He currently reports to the President of R&D and part of the World-Wide Research and Development Leadership Team. He is currently leading a multi- functional global team which includes Biostatisticians, Clinical Pharmacologists, Clinicians, Precision Medicine Scientists and Digital Medicine Scientists.
    Sandeep has extensive experience in late phase studies and with regulatory interactions especially with the FDA (US Agency), EMA (European Agency) and PMDA (Japan Agency). He is internationally known for his technical expertise especially in the area of adaptive designs, personalized medicine, multi-regional trials, and small populations and has participated in the core review of draft version of the regulatory guidance documents. He has co-authored and co- edited six books and contributed to influential papers in this area. He has taught short courses internationally and is a regular invited speaker in academic, FDA, Industry forums and Business Management institutes.
     

    Simon Wandel

    Associate Director Statistical Methodologist, Novartis Pharmaceuticals
    Simon Wandel

    Simon Wandel holds a master in Statistics and a PhD in Medical Statistics/Epidemiology from University of Bern. In 2010, he joined Novartis as statistician. In 2013, he co-founded a start-up specialized for Bayesian statistics (Cogitars GmbH), before rejoining Novartis as Expert Statistical Methodologist in 2014.
    Simon Wandel has a particular interest in application of Bayesian statistics for clinical trials. He has worked as responsible or consulting statistician for more than 30 fully Bayesian phase I/II/IV trials. He regularly provides talks and trainings at meetings of professional societies and academic institutions and contributes to scientific sessions organized by regulatory agencies.
     

    Sofia Villar

    postdoctoral research associate , MRC Centre
    Sofia Villar

    Solange Corriol-Rohou

    Senior Director Regulatory Affairs and Policy, EU, AstraZeneca
    Solange Corriol-Rohou

    Solange Corriol-Rohou joined AZ R&D in 2004 and is currently Sr. Director Regulatory Affairs & Policy for Europe. She is a pulmonologist and an immuno-allergologist by training. Over the past 18 years, moving from the French Medicines Agency (formerly known as AFSSAPS) and a specialist physician position at the Hospital of Versailles (France) to the pharmaceutical industry, she has gained strategic experience in drug development for different therapy areas, such as respiratory and inflammation. Solange, in her role as the chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Clinical Development Expert Group has organized jointly with the European Medicines Agency (EMA) several workshops (e.g. on Adaptive Designs, Modelling & Simulation in 2011, Dose Finding/Dose Response in 2014, Paediatric Extrapolation in 2016). She has also experience working in Innovative Medicines Initiative (IMI) projects. With the PROactive consortium she developed and qualified PROs for COPD patients. As the deputy project leader of the IMI ADAPT SMART project, with all stakeholders (regulators, HTA/payers, patients’ organisations) involved in the consortium, she contributed to align understanding of the impact of MAPPs (Medicine Adaptive Pathways to Patients), to share learnings between all stakeholders, and to allow the field to actively work towards MAPPs implementation. Within ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), as the EFPIA topic leader, she has participated in the revision of the ICHE11 paediatric guideline and is currently keeping the momentum with the ICHE11A Paediatric Extrapolation Guideline which should be released in 2020.

     

    Tom Parke

    Director of Software Solutions, Berry Consultants, LLP
    Tom Parke

    Tom Parke is Director of Software Solutions for Berry Consultants. Tom joined Berry Consultants in 2016 having previously worked at Tessella, a UK scientific software company where he first met and worked with Don Berry. In 1998 Tom managed the development and running of a software system to support Pfizer’s ASTIN Stroke trial – a ground breaking response adaptive randomization dose ranging trial designed by Don Berry and Peter Mueller.
    Following that he managed multiple projects to support different aspects of many adaptive clinical trials, mostly designed by Berry Consultants, and projects to develop clinical trial simulators, first with Pfizer, then Wyeth, and finally with Eli Lilly to develop FACTS. Latterly, as well as managing the continuing development of FACTS, Tom has researched the estimation of expected Net Present Value of development programs leading to the development of the QUOTES software package.
    Tom originally graduated with joint First Class Honors in Maths and Computer Science from Bristol University, and enjoyed two decades in the software industry (inmos, Imperial Software Technology and then Praxis - which became part of Deloittes) before stumbling upon the wonderful world of adaptive clinical trials.
     

    Supporters

    Workshops

    The FDA – a new guidance on adaptive designs
    Workshop

    The FDA – a new guidance on adaptive designs

    Holiday Inn Kensington Forum
    3rd April 2019
    London, United Kingdom

    Design and analysis of clinical trials evaluating novel digital technologies
    Workshop

    Design and analysis of clinical trials evaluating novel digital technologies

    Holiday Inn Kensington Forum
    3rd April 2019
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Speaker Line-up

    Download

    2018 ATTENDEES

    Download

    2019 Programme

    Download

    Workshop B

    Download

    Workshop A

    Download

    Presentation by M.Beatrice Panico, Medical Assessor, MHRA

    Download

    Presentation by Professor Sue Todd, University of Reading, UK

    Download

    Presentation by Bob Clay, Managing Director, Highbury Regulatory Science

    Download

    Presentation by Dr. Frank Fleischer, Boehringer Ingelheim

    Download

    Presentation by Christine Fletcher, Amgen

    Download

    Media Partners


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    pharmanews hq

    Supporters
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out